SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Young and Older Folk Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: chowder11/12/2025 3:06:29 PM
3 Recommendations

Recommended By
Menominee
Tam3262
Three1auto

   of 23915
 
For those of you interested in PFE ...

Pfizer Raises Metsera Bid, Dividend Outlook Unchanged


Reaffirmed on November 12, 2025


Pfizer's outlook remains largely unchanged after the company agreed to pay nearly $10 billion for obesity-drug maker Metsera following a bidding war with Novo Nordisk.

The higher price tag, nearly double what was reported in September, will likely push debt above management’s 2.7x gross leverage target to around 3.1x to 3.2x.

Even so, the increase appears manageable and shouldn't affect Pfizer's strong A credit rating or its ability to maintain the dividend. As such, we are reaffirming Pfizer's Borderline Safe Dividend Safety Score.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News